Loading clinical trials...
Loading clinical trials...
Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous PNT001 in Hospitalized Patients With Traumatic Brain Injury (TBI)
Conditions
Interventions
PNT001
%5 dextrose for infusion
Locations
1
United States
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania, United States
Start Date
March 29, 2021
Primary Completion Date
April 12, 2021
Completion Date
April 12, 2021
Last Updated
June 29, 2022
NCT04521881
NCT07455136
NCT06725108
NCT06734026
NCT07357090
NCT06467708
Lead Sponsor
Pinteon Therapeutics, Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions